Quick Answer
Arcus Biosciences, Inc. reported Cash And Cash Equivalents At Carrying Value of $222.00 million for the year ending 2025.
- Arcus Biosciences, Inc. showed an increase of +48.0% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Arcus Biosciences, Inc.'s annual report (Form 10-K), filed with the SEC on February 25, 2026.
- XBRL data for this metric is available from 2015 to 2025 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2017: $39.10 million | Q2 2017: $29.62 million | Q3 2017: $18.31 million | Q1 2018: $198.12 million | Q2 2018: $170.00 million | Q3 2018: $74.89 million | Q1 2019: $68.50 million | Q2 2019: $76.07 million | Q3 2019: $78.99 million | Q1 2020: $67.33 million | Q2 2020: $285.19 million | Q3 2020: $221.85 million | Q1 2021: $390.26 million | Q2 2021: $320.48 million | Q3 2021: $179.43 million | Q1 2022: $549.00 million | Q2 2022: $273.00 million | Q3 2022: $218.00 million | Q1 2023: $238.00 million | Q2 2023: $230.00 million | Q3 2023: $184.00 million | Q1 2024: $185.00 million | Q2 2024: $156.00 million | Q3 2024: $201.00 million | Q1 2025: $192.00 million | Q2 2025: $248.00 million | Q3 2025: $238.00 million.
- Over the full 11 years of available data (2015 to 2025), Arcus Biosciences, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 373.7%.
- Historical annual values: Fiscal year 2025: $222.00 million | Fiscal year 2024: $150.00 million | Fiscal year 2023: $127.00 million | Fiscal year 2022: $206.00 million | Fiscal year 2021: $148.00 million | Fiscal year 2020: $173.42 million | Fiscal year 2019: $57.94 million | Fiscal year 2018: $71.06 million | Fiscal year 2017: $98.43 million | Fiscal year 2016: $65.16 million | Fiscal year 2015: $46.87 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: